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Available online 14 September 2017CXCL14 is a primordial chemokine that plays multiple roles in tumor suppression, autoimmune arthritis, and
obesity-associated insulin resistance. However, the underlying molecular mechanisms are unclear. Here, we
show that CXCL14 transports various types of CpG oligodeoxynucleotide (ODN) into the endosomes and lyso-
somes of bone marrow-derived dendritic cells (DCs), thereby activating Toll-like receptor 9 (TLR9). A combina-
tion of CpG ODN (ODN2395) plus CXCL14 induced robust production of IL-12 p40 by wild-type, but not Tlr9-
knockout, DCs. Consistent with this, ODN2395-mediated activation of DCs was significantly attenuated in
Cxcl14-knockout mice. CXCL14 bound CpG ODN with high affinity at pH 7.5, but not at pH 6.0, thereby enabling
efficient delivery of CpG ODN to TLR9 in the endosome/lysosome. Furthermore, the CXCL14-CpG ODN complex
specifically bound to high affinity CXCL14 receptors on DCs. Thus, CXCL14 serves as a specific carrier of CpG
DNA to sensitize TLR9-mediated immunosurveillance.Tanega






Innate immune responses are initiated bymicrobe-derived products
known as pathogen-associated molecular patterns (PAMPs) (Blasius
and Beutler, 2010; Kawai and Akira, 2010). PAMPs activate pattern rec-
ognition receptors (PPRs) expressed on or in dendritic cells (DCs),
thereby triggering inflammatory reactions, interferon responses, and
DCmaturation; these are followed byactivation of the adaptive immune
response that completely eliminates the pathogen (Blasius and Beutler,
2010; Kawai and Akira, 2010). Among the known PPRs, Toll-like recep-
tor 9 (TLR9) recognizes unmethylated cytosine-phosphate guanine
(CpG)-containing DNA (CpG DNA) present in bacterial DNAs; this type
of DNA is less abundant in mammalian genomic DNA (Hemmi et al.,
2000; Ishii and Akira, 2006). Thus, unmethylated CpGDNAacts as a sen-
sor for TLR9-mediated immunosurveillance (Krug et al., 2004a,b; Lund
et al., 2003; Tabeta et al., 2004).
Basic and clinical research studies have used synthetic CpG
oligodeoxynucleotide (CpG ODN) as a ligand for TLR9 (Krieg, 2006;shima),
s an open access article underIshii and Akira, 2006). Agonistic CpG ODN molecules fall into four
main categories, A, B, C, and P, based on their structure and function.
A-class CpG ODNs possess poly-G and palindromic sequences that
have strong interferon-α-inducing activity in plasmacytoid DCs
(pDCs). B-class CpG ODNs do not contain palindromic sequences and
predominantly act on B cells. C-class CpG ODNs have the properties of
both A-class and B-class molecules, and include palindromic sequences
at the 3′-end. P-class CpG ODNs have two copies of a palindromic se-
quence and are more potent than C-class molecules with respect to in-
duction of cytokine production.
Since TLR9 is localized within the endosomes and lysosomes of DCs,
CpG DNA must be internalized prior to binding. CpG ODNs bind to
DEC205 and mannose receptors to trigger TLR9-dependent responses
(Lahoud et al., 2012; Caminschi et al., 2013; Moseman et al., 2013).
Granulin, HMGB1, LL-37, and β-defensin also facilitate incorporation
of CpG ODNs (Park et al., 2011; Ivanov et al., 2007; Hurtado and Peh,
2010; Tewary et al., 2013). Some of these secreted factors directly
bind to CpG ODNs (Park et al., 2011; Ivanov et al., 2007; Tewary et al.,
2013); however, it is not clear how CpG ODNs are transported into
DCs to activate the TLR9 signaling.
CXCL14 is a non-ELR (glutamic acid-leucine-arginine) chemokine
with multiple immunological functions (Lu et al., 2016; Hara and
Tanegashima, 2012). At very high concentrations, CXCL14 acts as athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Tanegashima, 2012). Consistent with this, CXCL14 promotes NK
cell-mediated suppression of transplanted melanoma cell metastasis
in a CXCL14 transgenicmouse line (Hata et al., 2015). CXCL14 transgen-
ic mice with collagen-induced arthritis show augmented Th1 responses
(Chen et al., 2010). Conversely, Cxcl14-knockout (KO)mice showweak-
er inflammatory responses when they become obese (Nara et al., 2007).
Although these results clearly indicate that CXCL14 is involved in Th1
immune responses, the underlying molecular mechanisms require
clarification.
Since CXCL14 is abundantly present in mucosal tissues (the
Human Protein Atlas: http://www.proteinatlas.org/ENSG00000145824-
CXCL14/tissue) and displays anti-microbial activity, we speculated that
CXCL14 might be involved in innate immunity. Here, we demonstrate
that CXCL14 specifically binds CpG DNAs, delivers them to the
endosomal/lysosomal compartments in DCs via receptor internalization,
and efficiently activates TLR9-mediated cytokine production and DC
maturation.2. Materials and Methods
2.1. Mice and Cell Preparation
C57BL/6Nmicewere obtained fromNihon SLC (Hamamatsu, Japan).
As previously described (Tanegashima et al., 2010), Cxcl14−/−male and
Cxcl14+/− female mice with a C57BL/6 N background were crossed to
produce Cxcl14+/− and Cxcl14−/− mice. LysM-Cre knock-in mice
(Clausen et al., 1999) were obtained from RIKEN (RBRC02302), and
CD11c-Cre (stock number 007567) and Cxcr4F/F (stock number
008767) mice were obtained from the Jackson Laboratory (Bar Harbor,
ME). Tlr9-KO mice (Hemmi et al., 2000) were obtained from Oriental
Bioservice, Inc. (Kyoto, Japan).
BMDCs were prepared from 6-week-old C57BL/6N, Tlr9-KO, and
Cxcr4-CKOmice by culturing bonemarrow cells in RPMI-1640 medium
(Nacalai Tesque, Kyoto, Japan) containing 10% fetal bovine serum
(Thermo Fisher Scientific, Waltham, MA), mouse granulocyte-macro-
phage colony stimulating factor (10 ng/ml; Peprotech, Rocky Hill, NJ),
and mouse IL-4 (10 ng/ml; Peprotech) for 10 days. Splenocytes were
prepared from spleen removed from 6 to 8 week-old C57BL/6N mice.
Red blood cells were lysed in RBC lysis buffer (140 mM NH4Cl, 17 mM
Tris-HCl, pH 7.6). All mice were housed in a pathogen-free animal facil-
ity under a 12 h light/dark cycle. All experimental procedures were pre-
approved by the ethical committee of Tokyo Metropolitan Institute of
Medical Science.2.2. Reagents
Endotoxin-free ODN2395 was purchased from InvivoGen
(San Diego, CA). ODN2395mut (phosphorothioester modified sequence),
5′Cy3-ODN2395, 5′Cy3-ODN2395(p), 5′Cy3-ODN2395mut(p), ODN1826,
ODN1826(p), 5′Cy3-ODN1826, 5′Cy3-ODN1826(p), ODN1585(p), 5′Cy3-
ODN1585(p), ODN-D-SL03, 5′Cy3-ODN-D-SL03, ODN21798, 5′Cy3-
ODN21798, ODN1668, ODN1668(p), 5′Cy3-ODN1668, 5′Cy3-
ODN1668(p), and 5′Cy3-D35 were synthesized by Eurofins Geno-
mics (Tokyo, Japan). D35 was purchased from Gene design (Osaka,
Japan). CXCL14, CXCL14-K-biotin (referred to as CXCL14-bio in this
study), and CXCL14-Alexa488 were chemically synthesized (Tsuji
et al., 2015) based on the human CXCL14 sequence (Supplementary
methods and Fig. S1). Synthetic CXCL14was as active as recombinant
CXCL14 in terms of the inhibition of CXCL12-mediated cell migra-
tion. The endotoxin level of the synthetic CXCL14 preparation was
b0.1 EU/mg, as measured by a LAL Quantitation Kit (Thermo Fisher
Scientific). LPS, Poly-U, and Poly-IC were purchased from Sigma-Al-
drich (St. Louis, MO).2.3. Antibodies
The following antibodies/conjugates were purchased:
Allophycocyanin (APC)-conjugated anti-CD3ε (TONBO, Cat# 20–0032,
RRID:AB_2621538, Burlingame, CA), fluorescein isothiocyanate (FITC)-
conjugated anti-CD8α (BioLegend, Cat# 100706, RRID:AB_312745,
San Diego, CA), APC-rat anti-CD45R/B220 (BioLegend, Cat# 103212,
RRID:AB_312997), Brilliant Violet (BV) 421-conjugated anti-CD11c
(BioLegend, Cat# 117329 RRID:AB_10897814), AlexaFluor488-anti-
CD11b (BioLegend), FITC-anti-CD19 (BioLegend, Cat# 152404
RRID:AB_2629813), FITC-anti-CD3ε (BioLegend, Cat# 100203
RRID:AB_312660), APC-anti-CD184 (CXCR4; BioLegend, Cat# 146508
RRID:AB_2562785), phycoerythrin (PE)-conjugated anti-MHC class II
(BD Biosciences, San Jose, CA), PE-anti-CD86 (BioLegend, Cat# 105106
RRID:AB_313159), mouse anti-EEA1 (eBioscience, San Diego, CA),
Alexa488-labeled goat anti-mouse IgG, and FITC-anti-LAMP1
(BioLegend, Cat# 121606 RRID:AB_572007).
2.4. FACS Analysis
BMDCs were stained with a BV421-labeled anti-CD11c antibody to
confirm DC differentiation. Splenic cells were stained to identify CD8+
cDCs (BV421-CD11c+/FITC-CD8+/APC-CD3ε−/APC-CD45R/B220−),
CD11b+ cDCs (BV421-CD11c+/Alexa488-CD11b+/APC-CD3ε−/APC-
CD45R/B220−), and pDCs (BV421-CD11c+/FITC-CD19−/FITC-CD3ε−/
APC-CD45R/B220+). Cells were analyzed using a LSR Fortessa X-20
cytometer (BD Biosciences).
2.5. FACS and Microscopic Analyses of Incorporated CpG ODNs
BMDCs were plated onto 24 well plates (105 cells/well; Corning,
Corning, NY) and incubated for 1 h at 37 °C with Cy3-ODNs in the pres-
ence or absence of CXCL14 or CXCL12 in RPMI-1640medium containing
20mMHepes-NaOH, pH 7.5, and 0.1% BSA (Sigma, fatty acid free). Cells
were then trypsinized, stained with BV421-labeled anti-CD11c, and an-
alyzed by FACS.
For confocal microscopy analysis, BMDCs were plated onto 35 mm
glass plates (IWAKI, Tokyo, Japan) and incubated for 1 h at 37 °C with
CXCL14-Alexa488, Cy3-ODN2395, or Cy3-ODN2395 + CXCL14 in
RPMI-1640/20 mM Hepes-NaOH pH 7.5/0.1% BSA. Cells were then
fixedwith 4% paraformaldehyde/PBS for 1 h, permeabilized in 0.04% Sa-
ponin/PBS (Wako, Osaka, Japan), and stained with anti-EEA1 or anti-
LAMP1 antibodies. Fluorescent images were analyzed using a Leica
TCS SP8 confocal microscope (Leica Microsystems, Wetzlar, Germany).
2.6. Enzyme-Linked Immunoassay (ELISA)
BMDCs were plated onto 24-well plates (105 cells/well) (Corning)
and incubated in RPMI-1640/20 mM Hepes-NaOH pH 7.5/0.1% BSA for
6 h at 37 °C with CpG ODNs in the presence or absence of CXCL14 or
CXCL12. Culture supernatants were then tested using ELISA MAX™
Kits (BioLegend).
2.7. In Vitro Binding Assay
CXCL14-bio (10 pmol) was coupled to streptavidin-agarose (Sigma-
Aldrich) and incubatedwith Cy3-ODN [100 nM in 100 μl of bindingbuff-
er (50 mM Hepes pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1%
BSA)] for 1 h at 4 °C. Precipitates were then washed and eluted in SDS
sample buffer at 70 °C for 10 min. Cy3-ODN was separated by TBE-
Urea-SDS polyacrylamide gel electrophoresis, and Cy3 fluorescence
was measured in a LAS-3000 (Fuji Film, Tokyo, Japan). CXCL14-bio
was blotted onto a PVDF membrane and incubated with peroxidase-
conjugated streptavidin (GE Healthcare, Pittsburgh, PA). Chemilumi-
nescence detectionwas performed using the ECL Plus detection reagent
(GE Healthcare), and signals were measured in a LAS-3000.
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CXCL14-bio [10 pmol for ODNor 100pmol for ODN(p)]was incubat-
ed for 1 h at 4 °C with streptavidin-agarose and Cy3-ODN in 100 μl of
50 mM Hepes pH 7.5/150 mM NaCl/1 mM CaCl2/1 mM MgCl2/1% BSA.
The supernatant was collected and used as free Cy3-ODN. Bound Cy3-
ODN was eluted by heating at 56 °C for 1 h in 100 μl of elution buffer
[Tris-HCl pH 7.5, 200 mM NaCl, 5 mM EDTA, 1% SDS, proteinase K
(0.02 mg/ml)]. Cy3 fluorescence was then measured in a Varioskan
Flash apparatus (Thermo Fisher Scientific). The bound/free ratio was
then plotted against bound Cy3-ODN (nM). The slope of the liner re-
gression line was determined, and Kd was calculated as follows:−1 di-
vided by the slope of the liner regression line.
2.9. Cell Surface Binding Assay
293 T cells were transfected with a pCS2 + mouse Dec205 expres-
sion vector using polyethyleneimine HCl MAX (Polysciences, Warring-
ton, PA). Twenty-four hours after transfection, BMDCs, 293 T cells, and
Dec205-transfected 293 T cells were trypsinized, resuspended in
50 mM Hepes pH 7.5/150 mM NaCl/1 mM CaCl2/1 mM MgCl2/1% BSA,
and incubated with Cy3-ODN2395 in the presence or absence of
CXCL14 for 1 h at 4 °C. Cells were then subjected to FACS using a LSR
Fortessa X-20 cytometer. Data were analyzed using GraphPad Prism
software (GraphPad Software, La Jolla, CA).
2.10. In Vivo Administration of CpG ODNs
Serumwas collected frommice 3 days prior to injection and used as
a steady state sample. Three individualmice received an intravenous in-
jection of ODN2395 (20 nmol), and serum and spleen samples were ob-
tained 24 h later.
2.11. Statistical Analyses
Each of in vitro experiments was done more than twice with tripli-
cate samples. All statistical analyses were performed using Microsoft
Excel and an unpaired Student's t-test. Bar graphs present data as the
mean ± standard error. The mean fluorescent intensity and the
percentage of Cy3high cells were calculated by FlowJo software (Tomy
Digital, Tokyo, Japan). A P-value b 0.05 was considered significant.
3. Results
3.1. Hypothesis of CXCL14 and DNA Interaction
Since an isoelectric point of CXCL14 is 10.3, we suspected that
CXCL14 might bind to DNA. We first noticed that CXCL14 and plasmid
DNA produced insoluble precipitates when they were mixed together
(Fig. S2a). More importantly, CXCL14 promoted incorporation of GFP
expression vector into HeLa cells (Fig. S2b). Since CXCL14 is known to
be involved in the Th1-associated inflammation, we tested the possibil-
ity that CXCL14 functionally interacts with CpG ODNs, strong inducers
of Th1 response.
3.2. CXCL14 Promotes Internalization of CpG DNA by DCs
First of all, we performed FACS-based internalization assays of Cy3-
labeled CpGODNs. Mouse bonemarrow-derived DCs (BMDCs) were in-
cubated with Cy3-labeled ODN2395(p), a representative C-class CpG
ODN (Roda et al., 2005) [(p) denotes ODN containing natural phospho-
diester bonds], in the presence or absence of CXCL14. BMDCs incorpo-
rated very little Cy3-ODN2395(p) alone; however, internalization was
enhanced markedly by addition of 300 nM CXCL14 [Fig. 1a (upper
panels) and 1b]. CXCL14 also increased uptake of Cy3-ODN2395
(phosphorothioated form) by BMDCs [Fig. 1a (lower panels) and 1b];ODN2395 has been used widely in vaccine adjuvant studies in the
past. Internalization was weak when we tested CXCL12, excluding the
possibility that DNA bound to CXC-type chemokines non-specifically.
Moreover, we also observed CXCL14-assisted incorporation of Cy3-
ODN2395(p) and Cy3-ODN2395 by CD11c+CD8+ conventional DCs
(cDCs) (Fig. 1c and d), CD11c+CD11b+ cDCs, and plasmacytoid DCs
(pDCs) isolated from mouse spleens (Fig. S3).
3.3. CXCL14 Interacts With Various Types of CpG ODN
Next, we examined the effect of CpG ODN sequence/structure on its
transportation by CXCL14. The sequences of the CpG ODNs examined
are shown in the Table 1. First, in the presence of CXCL14, BMDCs incor-
porated Cy3-ODN2395mut(p) (inwhichCpGdinucleotides are replaced
by GpC dinucleotides) as efficiently as Cy3-ODN2395(p) (Fig. 1e and f),
suggesting that the CpG sequence has no effect on CXCL14-mediated in-
tracellular transport. Next, we found that CXCL14 did not support
internalization of Cy3-ODN1826(p), a representative B-class CpG
ODN lacking a palindromic structure (Fig. 1e and f). However,
uptake of Cy3-ODN1826 (phosphorothioated form) was enhanced
(Fig. S4). ODN1668 is another B-class CpG ODN, which is specific to
mouse (Heit et al., 2004). As was observed in ODN1826, CXCL14 sup-
ported internalization of phosphorothioated Cy3-ODN1668, but not
phosphodiestered Cy3-ODN1668(p) (Fig. S5). Finally, we found that
Cy3-ODN1585(p), a representative A-class CpG ODN, was incorporated
by BMDCs, and that thiswasnot enhancedbyCXCL14 (Fig. 1e and f).We
found it interesting that CXCL14 also promoted transport of a methylat-
ed form of ODN2395, albeit at a slightly reduced rate (Fig. 1g and h).
CXCL14 also increased intracellular transport of ODN-D-SL03 (C-class),
ODN21798 (P-class), and D35 (A-class), all of which are highly potent
CpG ODNs (Yang et al., 2013; Samulowitz et al., 2010; Gursel et al.,
2002) (Fig. S4). Taken together, these data suggest that CXCL14 recog-
nizes a sequence/structure common to C-class, phosphorothioated
form of B-class, P-class, and a part of A-class CpG ODNs.
3.4. Co-localization of CpGODN and CXCL14Within the Endosome/Lysosome
We next used confocal microscopy to examine whether CpG ODN is
internalized together with CXCL14. When BMDCs were incubated with
Cy3-ODN2395 plus CXCL14 C-terminally conjugated to Alexa488
(CXCL14-Alexa488), almost all Cy3-positive foci in the peri-nuclear re-
gion were positive for CXCL14-Alexa488, suggesting co-localization
(Fig. 2a). Although CXCL14-Alexa488 was also incorporated by BMDCs
in the absence of Cy3-ODN2395, the fluorescent signals were weaker
(Fig. 2a). Moreover, very weak Cy3 signals were detected when
BMDCs were incubated with Cy3-ODN2395 alone (Fig. 2b and c).
Next, we examined the subcellular localization of internalized CpG
ODN/CXCL14. Cy3-ODN2395/CXCL14-loaded BMDCs were stained
with an antibody specific for EEA1 (an endosome marker) or LAMP1
(a lysosome marker). The Cy3-positive foci merged with the EEA1 and
LAMP1 signals (Fig. 2b and c). These results indicate that CXCL14 acts
as a carrier molecule that escorts C-class CpG ODNs to the endosomal/
lysosomal compartments.
3.5. CXCL14 Supports CpG ODN-mediated Cytokine Production and DC
Maturation
Since CpG ODN is an agonistic ligand for TLR9, we investigated the
cytokine-inducing capacity of CXCL14 using BMDCs as a readout for
the TLR9 signal. A combination of ODN2395 and CXCL14 induced
much greater production of interleukin (IL)-12 p40, IL-6, and tumor ne-
crosis factor (TNF)-α than either molecule alone (Fig. 3a–c). A negative
control, ODN2395mut (which lacks TLR9 binding capacity), had no ef-
fect on cytokine production in the presence of CXCL14. Importantly,
CXCL14 had no synergistic effect on production of IL-12 p40 and IL-6
in the presence of polyinosinic-polycytidylic acid (poly-IC) or
Fig. 1. CXCL14 induces transport of CpG ODN into bonemarrow-derived dendritic cells (BMDCs). (a) FACS analysis of CD11c+ BMDCs incubatedwith 100 nMCy3-ODN2395(p) or 30 nM
Cy3-ODN2395 in the presence or absence of 300 nM CXCL14 or CXCL12 at 37 °C for 1 h. (b) Percentage of Cy3-ODNhigh cells in (a). (c) FACS analysis of CD11c+/CD8+ splenic DCs
(CD8+cDC) incubated with 100 nM Cy3-ODN2395(p) or 30 nM Cy3-ODN2395 in the presence or absence of 300 nM CXCL14. (d) Percentage of Cy3-ODNhigh cells in (c). (e) FACS
analysis of CD11c+ BMDCs incubated with 100 nM Cy3-ODN2395mut(p), 100 nM Cy3-ODN1826(p), or 100 nM Cy3-ODN1585(p) in the presence or absence of 300 nM CXCL14. (f)
Percentage of Cy3-ODNhigh cells in (E). (g) FACS analysis of CD11c+ BMDCs incubated with 30 nM Cy3-ODN2395 or 30 nM Cy3-ODN2395(5meC) in the presence or absence of
300 nM CXCL14. (h) Percentage of Cy3-ODNhigh cells in (g). In a, c, e, and g, the Cy3-ODNhigh fractions are boxed. In b, d, f, and h, each value represents the mean ± standard error
(SE) (n = 3; *P b 0.05, **P b 0.01, ***P b 0.001; n.s., not significant).
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induced TNF-α production (Fig. 3c). These data indicate that CXCL14
is not involved in activating TLR3 and TLR7. Consistent with the FACS
data (Fig. 1a), we found that CXCL12 did not increase the ODN2395-me-
diated production of IL-12 p40, IL-6, and TNF-α by BMDCs (Fig. 3d–f).
Similar to ODN2395, CXCL14 increased production of IL-12 p40 and IL-
6 by BMDCs stimulated with ODN-D-SL03, ODN21798, ODN1826, and
ODN1668 (Fig. S6a, S6b, S5c, and S5d). D35 had no effect on the produc-
tion of IL-12 p40 and IL-6 by BMDCs (Fig. S6a and S6b). It is noteworthy
that D35-mediated IFN-α production by pDCswas inhibited by CXCL14;
the reason for this is unclear (Fig. S6c).Table 1
Sequences and structures of CpG ODNs.















mc, 5′methyl-cytosine.To verify that the synergistic activity of ODN2395 plus CXCL14 is de-
pendent on TLR9,we next examined cytokine production by BMDCs iso-
lated from Tlr9-KOmice. BMDCs from these mice did not produce IL-12
p40, IL-6, or TNF-α after stimulation with ODN2395 plus CXCL14
(Fig. 3g–i). For these experiments, lipopolysaccharide (LPS) was used
as a positive control.
Lastly, we compared cell surface expression of CD86, a representa-
tive T cell costimulatory molecule, by BMDCs stimulated with or with-
out ODN2395 plus CXCL14. ODN2395 induced low level expression of
CD86, but this increased markedly in the presence of CXCL14 (Fig. 3j













Fig. 2. Intracellular co-localization of CpGODNand CXCL14. (a) Fluorescence images of BMDCs incubatedwith 1 μMAlexa488-conjugated CXCL14 in thepresenceor absence of 30 nMCy3-
ODN2395 at 37 °C for 1 h. (b, c) Fluorescence images of BMDCs incubated with 30 nM Cy3-ODN2395 in the presence or absence of 300 nM CXCL14 at 37 °C for 1 h. Cells were fixed and
stained with an anti-EEA1 antibody, followed by an Alexa488-conjugated secondary antibody (b) or a FITC-conjugated anti-LAMP1 antibody (c).
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The co-localization and synergistic activities of CpG ODN and
CXCL14 led us to investigate whether they directly bind to each other.
We first synthesized biotinylated CXCL14 (CXCL14-bio), which retainsCpG ODN escort activity (Fig. S7). When Cy3-ODN2395 and CXCL14-
biowere incubated in a tube, they formed a stable complex thatwas pre-
cipitated by streptavidin-agarose beads (Fig. 4a). The Cy3-ODN2395/
CXCL14-bio was out-competed by excess unlabeled ODN2395, thereby
confirming a specific interaction (Fig. 4a). Furthermore, CXCL14
Fig. 3. Synergistic effects of CpGODNand CXCL14 inDCs. (a–c) BMDCswere treatedwith 100nMODN2395 (ODN), 100 nMODN2395mut (ODNmut), Poly-IC (1 μg/ml), or Poly-U (10 μg/ml)
in thepresence (+)or absence (−) of 300 nMCXCL14 at 37 °C for 6 h. (d–f) BMDCswere treatedwith 300 nMCXCL14 or CXCL12 in the presence or absence of 100 nMODN2395 at 37 °C for
6 h. (g–i) BMDCs fromWTor TLR9-KOmicewere incubatedwith 100nMODN2395 in thepresence or absence of 300 nMCXCL14 at 37 °C for 6 h. LPS (1 ng/ml)was used as a positive control.
In a–i, conditioned media were used in an ELISA to detect IL-12 p40 (a, d, g), IL-6 (b, e, h), or TNF-α (c, f, i). (j) BMDCs were treated with 100 nM ODN2395 in the presence or absence of
300 nM CXCL14 at 37 °C for 24 h. CD86 expression by CD11c+ BMDCs was examined by FACS. CD86+ fractions are boxed. (k) Percentage of each CD86+ population in (j). In A–I and K,
each value represents the mean ± SE (n= 3; *P b 0.05, **P b 0.01, ***P b 0.001; n.s., not significant).
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Fig. 4. Specific binding of CXCL14 to CpG ODN. (a, b) 100 nM Cy3-labeled CpG ODN was incubated with 100 nM biotinylated CXCL14 in the presence or absence of unlabeled CpG ODN
(1, 10, or 100× in A; 100× in B) at 4 °C for 1 h. The complex was then pulled down with streptavidin-agarose (SA). CpG ODN and CXCL14 in the precipitate were visualized by gel
electrophoresis and Western blotting with the indicated antibodies. (c–h) Scatchard plots. Different amounts of Cy3-labeled CpG ODN were subjected to a CXCL14 pulled-down assay.
Bound and free Cy3 fluorescence was quantified. (i) Cy3-labeled 100 nM ODN2395 was incubated with 100 nM biotinylated CXCL14 in the presence or absence of unlabeled ODN2395
at pH 7.5 or pH 6.0. CpG ODN and CXCL14 in the precipitate were visualized by gel electrophoresis and Western blotting with the indicated antibodies. (j) Cy3-labeled 100 nM
ODN2395 and 100 nM biotinylated CXCL14 were pulled down with SA. The reaction buffer was then replaced by a buffer at pH 6.0 (solid line) or pH 7.0 (broken line), and bound and
free Cy3 fluorescence was measured periodically.
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and Cy3-ODN1585(p), but not with Cy3-ODN1826(p), in the in vitro
binding assay (Fig. 4b).
We next performed Scatchard plot analyses. The data revealed that
CXCL14 bound specifically to ODN2395, ODN2395(5meC), ODN2395(p),
ODN2395mut(p), ODN1585(p), ODN-D-SL03, ODN21798, ODN1826,
ODN1668 and D35, with Kd values of 9–100 nM (Fig. 4c–h, Fig. S8a–d,
S8f, and Table 1). We did not detect a specific interaction of CXCL14with ODN1826(p) (Fig. 4g) and an extremely weak interaction with
ODN1668(p) (Kd = 1.25 μM) (Fig. S8e). ODN1585(p) was transported
into DCs in a CXCL14-independent fashion (Fig. 1e and f). Importantly,
methylation of cytosine residues within ODN2395 reduced its affinity
for CXCL14 by nearly 10-fold (Fig. 4d), which accounts for the slight re-
duction in incorporation by DCs (Fig. 1g and h).
Since TLR9 is localized to acidic intracellular compartments, we ex-
amined the pH sensitivity of the complex. CXCL14 and Cy3-ODN2395
254 K. Tanegashima et al. / EBioMedicine 24 (2017) 247–256formed a stable complex at pH 7.5, but not at pH 6.0 (Fig. 4i). Cy3-
ODN2395 was released from the complex as early as 7 min after
switching the pH of the reaction buffer from 7.5 to 6.0 (Fig. 4j). This
CpG ODN-binding property of CXCL14 is opposite to that of TLR9
(Ohto et al., 2015), ensuring efficient transfer of CpG ODN from
CXCL14 to TLR9 in the endosomal/lysosomal compartment.
3.7. CXCL14 is Required for ODN2395-mediated DC Maturation and
Cytokine Production
We next examined the physiological relevance of CXCL14-mediated
activation of TLR9 signaling using Cxcl14-KO mice. Cxcl14+/− and
Cxcl14−/− mice intravenously received 20 nmol of ODN2395, followed
bymeasurement of both plasma IL-12 p40 concentrations and activated
DC numbers. ODN2395 increased IL-12 p40 levels in Cxcl14+/− mice at
24 h post-administration; however, this was not the case in Cxcl14−/−
mice (Fig. 5a). There was no difference in plasma IL-6 concentrations
between Cxcl14+/− and Cxcl14−/− mice before and after ODN2395 ad-
ministration (Fig. S9).
The numbers of activated MHC class IIhigh DCs in both the
CD11c+CD8+ and CD11c+CD11b+ populations from CXCL14−/− mice
after ODN2395 administration were markedly lower than those from
Cxcl14+/− mice (Fig. 5b and c). The steady state number of DCs was
similar in Cxcl14+/− and Cxcl14−/− mice. These results suggest that
CXCL14 regulates CpG ODN (ODN2395)-induced DC activation in vivo.
3.8. The CXCL14/CpG ODN Complex is Transported into Cells via CXCL14
Receptors
How is the CpG ODN/CXCL14 complex transported across the
plasma membrane of DCs? To answer this question, we carried outFig. 5. In vivo responses of Cxcl14-KOmice to ODN2395. (a) Mice received an intravenous injec
and concentration of IL-12 p40was determined by ELISA. (b) Spleenswere dissected, and expre
analysis. The MHC class IIhigh fraction is boxed. (c) The percentage of MHC class IIhigh cells in (bFACS-based assays to measure binding of Cy3-ODN2395 to BMDCs.
Very little Cy3-ODN2395 bound to BMDCs; however, binding increased
markedly upon addition of CXCL14 (Kd = 13 nM) (Fig. 6a). DEC205 is a
receptor for CpG DNA in DCs (Lahoud et al., 2012). Consistent with this,
we found that overexpression of Dec205 in 293 T cells increased Cy3-
ODN2395 binding (Fig. 6b). However, the Cy3-ODN2395-binding ca-
pacity of Dec205-transfected 293 T cells was not augmented by
CXCL14 (Fig. 6b). This indicates that DCsmay have distinct receptors re-
sponsible for transport of CpG ODN/CXCL14.
Although the molecular component(s) of CXCL14 receptors have not
been fully elucidated, we previously reported that CXCL14 binds to
CXCR4 with high affinity (Tanegashima et al., 2013). We suspected that
CXCR4might be involved in transporting the CpGODN/CXCL14 complex;
therefore, we prepared Cxcr4-deficient BMDCs from Cxcr4F/F:LysM-Cre
and Cxcr4F/F:CD11c-Cre mice (Fig. S10) and found that cell surface bind-
ing of Cy3-ODN2395 to both Cxcr4-conditional KO (cKO) BMDCs and
control Cxcr4F/F BMDCswas strengthened by CXCL14 (Fig. 6c). Moreover,
Cxcr4F/F:LysM-Cre BMDCs stimulated with ODN2395/CXCL14 produced
IL-12 p40 in amounts comparable with those produced by Cxcr4F/F
BMDCs (Fig. 6d). Taken together, these data suggest that CXCR4 is not a
major internalization receptor for the CpG ODN/CXCL14 complex.
4. Discussion
CXCL14 is a pleiotropic chemokine with pro-inflammatory func-
tions. However, its physiological functions and associated underlying
molecular mechanisms remain to be clarified. We discovered that
CXCL14 forms a stable complex with CpG ODN prior to transport into
DCs, leading to a robust increase in expression of inflammatory cyto-
kines via activation of TLR9. We also showed that DCs express specific
receptors for the CpG ODN (ODN2395)/CXCL14 complex; thesetion of ODN2395 (20 nmol) as indicated. Serumwas obtained 24 h later from eachmouse,
ssion ofMHC class II by CD8+/CD11c+ and CD11b+/CD11c+ DCswas determined by FACS
). In A and C, each value represents the mean ± SE (n= 3; *P b 0.05; n.s., not significant).
Fig. 6. Specific binding of CpGODN/CXCL14 complex to receptors. (a) BMDCswere incubatedwith various concentrations of Cy3-ODN2395 in the presence or absence of 300 nMCXCL14 at
4 °C for 1 h. (b) 293 T cells or 293 T cells transfected with a DEC205 expression vector were incubated with the indicated concentrations of Cy3-ODN2395 in the presence or absence of
300 nM CXCL14. (c) BMDCs prepared from Cxcr4F/F, Cxcr4F/F:LysM-Cre, or Cxcr4F/F:CD11c-Cremice were incubatedwith the indicated concentrations of Cy3-ODN2395 in the presence or
absence of 300 nM CXCL14. In A–C, the mean fluorescence intensity of Cy3 bound to each cell sample is shown. (d) BMDCs from Cxcr4F/F and Cxcr4F/F:LysM-Cre mice were treated with
100 nMODN2395 in the presence or absence of 300 nMCXCL14 at 37 °C for 6 h. Conditionedmedia (n=3)were then used in an ELISA tomeasure IL-12 p40. LPS (1 ng/ml) was used as a
positive control. n.s., not significant.
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CpG ODN/CXCL14 complex dissociates rapidly in the acidic endosomal/
lysosomal compartments, CpG ODN is efficiently transferred to TLR9.
The blunted responses of Cxcl14-KO mice to CpG ODN confirmed that
CXCL14 plays a physiological role in TLR9-mediated DNA sensing.
CXCL16 promotes B-class CpG ODN-mediated activation of TLR9 in
DCs (Gursel et al., 2006). The present study is therefore the second to
show chemokine involvement in the TLR9 system; however, here we
provided the biochemical basis for the chemokine-DNA interaction.
Since TLR9 is present in the endosomal/lysosomal compartment, in-
ternalization of microbial unmethylated CpG DNA is the first event that
activates the TLR9 signaling pathway (Ishii and Akira, 2006). Here, we
show that CXCL14 induces internalization of CpG ODNs into DCs via
high affinity binding between 1) CpG ODNs and CXCL14, and 2) the
CpG ODN/CXCL14 complex and CXCL14 receptors. Previous studies
identified several CpG DNA receptors and secretory factors that facili-
tate internalization of CpG ODNs. Granulin, HMGB1, β-defensin, and
LL-37 act mainly on B-class CpG ODNs (Park et al., 2011; Ivanov et al.,
2007; Hurtado and Peh, 2010; Tewary et al., 2013). Because CXCL14 in-
teracts with various types of CpG ODNs, its spectrum is different from
that of previously described CpG ODN-associated molecules.
CXCL14 and bactericidal peptides share some biochemical proper-
ties with β-defensin and LL-37 (Dai et al., 2015). CXCL14 also possesses
bacteria-killing activity (Maerki et al., 2009). Indeed, clearance of Strep-
tococcus pneumoniae is significantly impaired in CXCL14-KO mice (Dai
et al., 2015). From the viewpoint of pathogen sensing, it is an advantage
if bactericidal peptides escort CpG DNAs into DCs and activate TLR9.
CXCL14 binds to CpG ODNswith amuch higher affinity than β-defensin
(Tewary et al., 2013).We also show that CXCL14 has reduced affinity for
methylated CpGODNs, implying that unmethylated bacterial CpG DNAs
could be preferentially bound by CXCL14. Thus, CXCL14 contributes to
anti-bacterial immune defenses by acting as a direct bactericidal pep-
tide and as a carrier protein for CpG DNA.
We demonstrated that DEC205 is not involved in transport of the
CpG ODN (ODN2395)/CXCL14 complex (Lahoud et al., 2012). Further-
more, Cxcr4-deficient DCs incorporated the CpG ODN/CXCL14 complexas efficiently as WT DCs. Although this does not officially rule out the
possibility that CXCR4 plays a role, it suggests the existence of other
CXCL14 receptormolecule(s). Identification of a responsible CXCL14 re-
ceptor molecule is necessary if we are to fully understand the mecha-
nism underlying CpG DNA/CXCL14-mediated activation of TLR9.
TLR9 first activates the innate immune response and then triggers
Th1 inflammatory responses linked to adaptive immunity (Krieg,
2006). Taking advantage of this property, CpG ODNs have been used
as adjuvants for vaccines against infectious diseases andmalignant can-
cers (Scheiermann and Klinman, 2014). Recent clinical trials of CpG
ODNs show favorable outcomes (Scheiermann and Klinman, 2014).
However, the efficacy of CpG ODN as a cancer vaccine adjuvant remains
unsatisfactory (Scheiermann and Klinman, 2014). Here, we show that
CXCL14 increases the efficiency with which CpG ODN is incorporated
into both cDCs and pDCs, even in the presence of low concentrations
of CpG ODN. Therefore, CXCL14 is a useful tool for delivering CpG
ODNs. Clinical trials have examined high doses of CpG7909 (B-class
ODN) as a cancer vaccine adjuvant (Murad et al., 2007; Scheiermann
and Klinman, 2014), suggesting that administration of other ODNs in
combination with CXCL14 is an attractive option for anti-cancer immu-
notherapy. This notion is supported by the results of a study showing
NK/NKT cell-dependent suppression of the growth of B16F10 melano-
ma and Lewis lung carcinoma in CXCL14 transgenic mice (Hata et al.,
2015). We are currently investigating the anti-tumor activity of this
combined vaccine adjuvant.
Recent studies show that extracellular self-DNAs trigger obesity-in-
duced inflammation via TLR9, resulting in insulin resistance (Revelo et
al., 2016; Nishimoto et al., 2016). However, it is unclear how these
DNAs are incorporated by macrophages or DCs prior to initiation of in-
flammatory responses. We previously showed that Cxcl14-KO mice
are resistant to obesity-induced diabetes (Nara et al., 2007). Since ex-
pression of CXCL14 is upregulated in adipose tissues upon obesity,
TLR9 signaling triggered by the CXCL14/self-DNA complex might con-
tribute to insulin resistance induced by chronic inflammation. Consis-
tent with this, a recent report shows that administration of a TLR9
inhibitory oligonucleotide (iODN) improves the insulin resistance of
256 K. Tanegashima et al. / EBioMedicine 24 (2017) 247–256obese mice (Nishimoto et al., 2016). If CXCL14 increases intracellular
transport of iODN, CXCL14might also be applicable as a therapy for obe-
sity-induced diabetes.
We recently developed a “one-pot” synthetic procedure to generate
a full length CXCL14 peptide (Tsuji et al., 2015). In terms of CpGODN es-
cort activity, the synthetic CXCL14molecule is superior to E. coli-derived
recombinant CXCL14 (unpublished data). Synthetic CXCL14 mutants
will be valuable tools for elucidating structure-function relationships
between CpG ODN and CXCL14. The discovery of a “minimum molecu-
lar module” that recognizes CpG would advance basic research into
adaptive immunity and open new clinical applications.
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